CDK7/9-IN-1 is a cyclin-dependent kinases 7/9 ( CDK7/9 ) inhibitor. CDK7/9-IN-1 selectively inhibits CDK7 over CDK9. CDK7/9-IN-1 inhibits CDK7 with IC 50 s of 0.0656 μM and 0.00574 μM without pre-incubation and after 3 hours pre-incubation, respectively. CDK7/9-IN-1 inhibits CDK9 with an IC 50 of 2.14 μM after 3 hours pre-incubation. CDK7/9-IN-1 can be used for the research of cancer.

CDK7/9-IN-1 (example 8; 0.001-20 μM; 4 h) inhibits CDK7 with an relative IC 50 of 0.0262 μM for phospho-carboxyl terminal domain (Rbp2) (Ser5) in HCT116 cells[1]. CDK7/9-IN-1 (0.001-20 μM; 4 h) inhibits CDK9 with an IC 50 of 2.59 μM for phospho-carboxyl terminal domain (Rbp2) (Ser2) in HCT116 cells[1]. CDK7/9-IN-1 (0.001-20 μM; 4 h) inhibits cMyc with an relative IC 50 of 0.0138 μM in HCT116 cells[1]. CDK7/9-IN-1 (20 μΜ, 2 μΜ, and 0.2 μΜ; 1 h) shows excellent selectivity against the 468 protein kinases panel. CDK7/9-IN-1 shows approximately 96% inhibition against CDK7[1].

2747919-19-1

C24H32F3N5O2

479.54

CDK7/9-IN-1

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years